公开(公告)号：US11767512B2

公开(公告)日：2023-09-26

申请号：US16604072

申请日：2018-04-13

Applicant: CELLECTIS ,  ALBERT-LUDWIGS-UNIVERSITAT FREIBURG

Inventor： Toni Cathomen ,  Tatjana Cornu ,  Philippe Duchateau ,  Claudio Mussolino ,  Marianna Romito ,  Agnes Gouble

IPC: C12N9/22 ,  C12N5/0789 ,  A61P31/18 ,  A61K35/17 ,  C07K14/715 ,  C12N15/90 ,  C12N15/85 ,  C12N15/67 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C12N5/0647 ,  A61K35/17 ,  A61P31/18 ,  C07K14/7158 ,  C12N5/0636 ,  C12N9/22 ,  C12N15/67 ,  C12N15/85 ,  C12N15/907 ,  A61K38/00

Abstract: The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.

公开(公告)号：US20230212613A1

公开(公告)日：2023-07-06

申请号：US17996733

申请日：2021-05-06

Applicant: CELLECTIS S.A.

Inventor： Ming YANG ,  Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Patrick HONG

IPC: C12N15/90 ,  C07K14/725 ,  C12N9/22 ,  C12N5/0783

CPC classification number: C12N15/907 ,  C07K14/7051 ,  C12N9/22 ,  C12N5/0636 ,  C12N2310/20

Abstract: The present disclosure provides methods for targeted insertion of an exogenous sequence at a genomic locus in a cell, wherein said insertion is induced by a sequence-specific endonuclease that has cleavage activity at said locus, at least 5 hours before the introduction into said cell of a DNA template comprising said exogenous sequence.

公开(公告)号：US20230201260A1

公开(公告)日：2023-06-29

申请号：US18056544

申请日：2022-11-17

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N15/85

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C07K16/2803 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C12N15/85 ,  C07K2317/622 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2502/99 ,  C07K2319/00 ,  C12N2501/39 ,  C12N2501/599 ,  A61K38/00

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US11578318B2

公开(公告)日：2023-02-14

申请号：US15956103

申请日：2018-04-18

Applicant: Cellectis S.A.

Inventor： Richard E Walters ,  Alan D King

IPC: C12N13/00 ,  C12M1/00 ,  C12N15/87 ,  C12M1/42 ,  C12M3/00 ,  C12M3/02 ,  H02K1/24 ,  H02K1/14 ,  H02K19/10 ,  A61K9/00

Abstract: An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm−1) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm3), wherein the geometric factor is less than or equal to 0.1 cm−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microSiemens/cm to 500 microSiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. treating the suspension enclosed in the chamber with one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the vesicles in the chamber is substantially uniform.

公开(公告)号：US11466291B2

公开(公告)日：2022-10-11

申请号：US16314697

申请日：2017-06-30

Applicant: CELLECTIS

Inventor： Jean-Pierre Cabaniols ,  Jean-Charles Epinat ,  Philippe Duchateau

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US11365430B2

公开(公告)日：2022-06-21

申请号：US16793918

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe Duchateau ,  André Choulika ,  Laurent Poirot

IPC: A61K35/17 ,  C12N15/85 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90 ,  C12N15/113

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20210161954A1

公开(公告)日：2021-06-03

申请号：US16498899

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Philippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/02 ,  A61K31/365 ,  C07K14/705 ,  C07K14/725

Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US10813951B2

公开(公告)日：2020-10-27

申请号：US15037988

申请日：2014-11-21

Applicant: CELLECTIS

Inventor： Julien Valton ,  Philippe Duchateau ,  David Sourdive

IPC: A61K35/17 ,  C12N5/0783 ,  A61K45/06 ,  A61K31/7076

Abstract: The present invention relates to the use of “off-the-shelf” allogeneic therapeutic cells for immunotherapy in conjunction with chemotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering allogeneic T-cell resistant to chemotherapeutic agents. The therapeutic benefits afforded by this strategy should be enhanced by the synergistic effects between chemotherapy and immunotherapy. In particular, the present invention relates to a method for modifying T-cells by inactivating at least one gene encoding T-cell receptor component and by modifying said T-cells to confer drug resistance. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.

公开(公告)号：US10752670B2

公开(公告)日：2020-08-25

申请号：US15575707

申请日：2016-05-20

Applicant: Cellectis

Inventor： Julianne Smith ,  Cècile Schiffer-Mannioui

IPC: C07K14/725 ,  A61K39/00 ,  C07K14/705 ,  C07K14/735 ,  C07K16/30 ,  C12N5/0783 ,  A61K38/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

公开(公告)号：US10709775B2

公开(公告)日：2020-07-14

申请号：US15751472

申请日：2016-07-26

Applicant: CELLECTIS

Inventor： Mathilde Dusseaux

IPC: A61K39/00 ,  C07K14/705 ,  C07K16/28 ,  A61K39/395 ,  C12N5/0783 ,  A61P35/00

Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.